Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 14 (3) , 101014
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- Merck
- Navigate BioPharma
This publication has 52 references indexed in Scilit:
- Biomarkers on melanoma patient T Cells associated with ipilimumab treatmentJournal of Translational Medicine, 2012
- Standardizing immunophenotyping for the Human Immunology ProjectNature Reviews Immunology, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up GuidelinesJournal of Clinical Oncology, 2010
- B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in MiceThe Journal of Immunology, 2010
- Features of responding T cells in cancer and chronic infectionCurrent Opinion in Immunology, 2010
- Negative Immune Regulator Tim-3 Is Overexpressed on T Cells in Hepatitis C Virus Infection and Its Blockade Rescues Dysfunctional CD4 + and CD8 + T CellsJournal of Virology, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004